Table 2.
Odds ratios (OR) for immune cell ratio and pancreatic cancer risk in cohorts (nested case-control study).
| Age-adjusted Model |
Multivariate-adjusted Modela |
|||
|---|---|---|---|---|
| Cases/Controls | OR (95% CI) | Case/Controls | OR (95% CI) | |
| CD4/CD8 Ratio | ||||
| Q1 (< 1.25) | 97 / 108 | ref. | 96 / 108 | ref. |
| Q2 (1.26 – 1.88) | 101 / 107 | 1.06(0.72, 1.56) | 100 / 107 | 1.07(0.72, 1.58) |
| Q3 (1.89 – 2.73) | 91 / 108 | 0.95(0.64, 1.41) | 90 / 106 | 0.97(0.65, 1.45) |
| Q4 (≥ 2.74) | 104 / 108 | 1.08(0.73, 1.58) | 104 / 107 | 1.10(0.74, 1.62) |
| p for continuous = 0.84 | p for continuous = 0.76 | |||
| Neutrophil/Lymphocyte Ratio | ||||
| Q1 (< 1.29) | 97 / 108 | ref. | 97 / 108 | ref. |
| Q2 (1.30 – 1.69) | 82 / 107 | 0.85(0.57, 1.27) | 82 / 106 | 0.85(0.57, 1.27) |
| Q3 (1.70 – 2.26) | 108 / 108 | 1.11(0.76, 1.63) | 106 / 107 | 1.09(0.74, 1.61) |
| Q4 (≥ 2.27) | 106 / 108 | 1.09(0.75, 1.60) | 105 / 107 | 1.10(0.75, 1.61) |
| p for continuous = 0.40 | p for continuous = 0.41 | |||
| B cell /Lymphocyte Ratio | ||||
| Q1 (< 0.10) | 96 / 108 | ref. | 96 / 106 | ref. |
| Q2 (0.11 – 0.13) | 84 / 107 | 0.89(0.60, 1.32) | 83 / 106 | 0.87(0.59, 1.30) |
| Q3 (0.14 – 0.17) | 100 / 108 | 1.05(0.71, 1.55) | 100 / 108 | 1.04(0.71, 1.54) |
| Q4 (≥ 0.18) | 113 / 108 | 1.19(0.81, 1.75) | 111 / 108 | 1.15(0.78, 1.71) |
| p for continuous = 0.26 | p for continuous = 0.34 | |||
| T cell/Lymphocyte Ratio | ||||
| Q1 (< 0.58) | 103 / 108 | ref. | 102 / 108 | ref. |
| Q2 (0.59 – 0.64) | 95 / 107 | 0.94(0.64, 1.38) | 93 / 106 | 0.94(0.63, 1.39) |
| Q3 (0.65 – 0.69) | 101 / 108 | 0.99(0.68, 1.46) | 101 / 108 | 1.01(0.69, 1.50) |
| Q4 (≥ 0.70) | 94 / 108 | 0.93(0.63, 1.37) | 94 / 106 | 0.97(0.65, 1.44) |
| p for continuous = 0.78 | p for continuous = 0.97 | |||
a
Adjusted for age, cohort, date of blood draw, and smoking.